Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic for hepatic cancer

A liver cancer and antibody technology, applied in the direction of antibody medical components, drug combinations, peptides, etc., can solve the problems of hindering chemotherapy agents and exacerbation

Inactive Publication Date: 2015-03-25
CHUGAI PHARMA CO LTD
View PDF33 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Sometimes the chemotherapeutic agent has to be stopped when these symptoms appear, and the exacerbation of the above symptoms is the main reason that prevents the use of the chemotherapeutic agent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic for hepatic cancer
  • Therapeutic for hepatic cancer
  • Therapeutic for hepatic cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0324] Effects of anti-glypican 3 antibody and chemotherapeutic agents (mitoxantrone or adriamycin hydrochloride) on mouse models transplanted with human liver cancer cell lines expressing glypican 3

[0325] (1) cell line

[0326] As human liver cancer cell lines expressing glypican 3, HuH-7 cells (Human Science Research Resource Bank) and HepG2 cells (ATCC) were used. HuH-7 cells were maintained and subcultured with Dulbecco's Modifid Eagle's Medium (SIGMA) containing 10% FBS (BIONET), and HepG2 cells were maintained and subcultured with sodium pyruvate (Invitrogen) containing 10% FBS, 1 mmol / l MEM, 1 mmol / l MEM was maintained and subcultured in Minimum Essential Medium Eagle medium (SIGMA) of non-essential amino acids (Invitrogen).

[0327] (2) Establishment of human liver cancer cell line transplanted mouse model

[0328] Each cell was prepared using a solution containing equal amounts of each subculture medium and MATRIGEL Matrix (BD Bioscience) so that it was 5×10 7 c...

Embodiment 2

[0345] Effects of humanized Glypican 3 antibody and chemotherapeutic agent (Sorafenib) on mouse models transplanted with human liver cancer cell lines expressing Glypican 3

[0346] 6-week-old male CB-17 SCID mice were purchased from CLEA Japan Inc. Immediately before tumor transplantation, 200 μg of anti-asialo-GM1 antibody (WAKO) was intraperitoneally administered to mice, and then subcutaneously transplanted 5×10 5 A dispersion obtained by dispersing HepG2 cells or HuH-7 cells in 50% Matrigel (Becton Dickinson). When the tumor volume reaches 250mm 3 At the moment, the mice were divided into groups, and the administration was started. The humanized anti-glypican 3 antibody (hGC33, WO2006006693) was formulated with PBS (-) at an appropriate concentration and administered intravenously once a week for 3 weeks. Sorafenib was synthesized according to the method described in Organic Process Research & Development (2002) 6, 777-781, suspended in pure water containing 10% ethano...

Embodiment 5

[0391] (1) Combined use of humanized Glypican 3 antibody and chemotherapeutic agent (Sorafenib) on mouse models transplanted with human liver cancer cell lines expressing Glypican 3

[0392] 6-week-old male CB-17 SCID mice were purchased from CLEA Japan Inc. Immediately before tumor transplantation, 200 μg of anti-asialo-GM1 antibody (WAKO) was intraperitoneally administered to mice, and then subcutaneously transplanted 5×10 5 A dispersion obtained by dispersing HepG2 cells in 50% Matrigel (Becton Dickinson). When the tumor volume reaches 250mm 3 At the moment, the mice were divided into groups, and the administration was started. The pH7pL16 antibody was prepared at an appropriate concentration with PBS(-) and administered intravenously once a week for 3 weeks. Sorafenib was synthesized according to the method described in Organic Process Research & Development (2002) 6, 777-781, suspended in pure water containing 10% ethanol and 10% Cremophor EL, and administered orally ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A novel pharmaceutical composition for treating or preventing hepatocellular carcinoma and a method of treatment are provided. A pharmaceutical composition for treating or preventing liver cancer is obtained by combining a chemotherapeutic agent with an anti-glypican 3 antibody. Also disclosed is a pharmaceutical composition for treating or preventing liver cancer which comprises as an active ingredient an anti-glypican 3 antibody for use in combination with a chemotherapeutic agent, or which comprises as an active ingredient a chemotherapeutic agent for use in combination with an anti-glypican 3 antibody. Using the chemotherapeutic agent and the anti-glypican 3 antibody in combination yields better therapeutic effects than using the chemotherapeutic agent alone, and mitigates side effects that arise from liver cancer treatment with the chemotherapeutic agent.

Description

technical field [0001] related application [0002] This application claims priority based on Japanese Patent Application No. 2008-98309 (filed on April 4, 2008) and International Application PCT / JP2008 / 002690 (filed on September 26, 2008), the contents of which are incorporated herein by reference. technical field [0003] The present invention relates to the field of a pharmaceutical composition for treating or preventing liver cancer or a treatment method using the pharmaceutical composition. The pharmaceutical composition is effective for treating liver cancer and combines a chemotherapeutic agent and a polyphosphatidylinositol protein. Sugar 3 antibody formed. Background technique [0004] It has been reported that about 600,000 deaths per year are caused by hepatocellular carcinoma, ranking fifth among the deaths caused by cancer in the world (Non-Patent Document 1). Most hepatocellular carcinomas die within 1 year of diagnosis of the disease. Unfortunately, hepat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/395A61K31/404A61K31/44A61K45/00A61P35/00A61P43/00
CPCA61K39/39558C07K2317/565A61K2039/505C07K16/303A61K31/404A61K31/44A61K45/06C07K2317/24A61P1/16A61P35/00A61P43/00A61K2300/00
Inventor 木下恭子杉本正道石黑敬弘
Owner CHUGAI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com